Literature DB >> 35788966

WNT/β-catenin Pathway: a Possible Link Between Hypertension and Alzheimer's Disease.

Alexandre Vallée1, Jean-Noël Vallée2,3, Yves Lecarpentier4.   

Abstract

PURPOSE OF REVIEW: Recent research has shown that older people with high blood pressure (BP), or hypertension, are more likely to have biomarkers of Alzheimer's disease (AD). Essential hypertension represents the most common cardiovascular disease worldwide and is thought to be responsible for about 13% of all deaths. People with essential hypertension who regularly take prescribed BP medications are half as likely to develop AD as those who do not take them. What then is the connection? RECENT
FINDINGS: We know that high BP can damage small blood vessels in the brain, affecting those parts that are responsible for memory and thinking. However, the link between AD and hypertension remains unclear. Recent advances in the field of molecular and cellular biology have revealed a downregulation of the canonical WNT/β-catenin pathway in both hypertension and AD. In AD, the glutamate transport function is decreased, a decrease that is associated with a loss of synapse and neuronal death. β-catenin signaling appears to act as a major regulator of glutamate transporters (EAAT and GS) expression and can be harnessed to remove excess glutamate in AD. This review focuses on the possible link between hypertension and AD through the decreased WNT/β-catenin which interacts with the glutamatergic pathway.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; Glutamate; Glutamate transporter; Hypertension; WNT/β-catenin pathway; β-catenin

Year:  2022        PMID: 35788966     DOI: 10.1007/s11906-022-01209-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   4.592


  99 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Synaptic plasticity, memory and the hippocampus: a neural network approach to causality.

Authors:  Guilherme Neves; Sam F Cooke; Tim V P Bliss
Journal:  Nat Rev Neurosci       Date:  2008-01       Impact factor: 34.870

Review 3.  Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment.

Authors:  J A Chung; J L Cummings
Journal:  Neurol Clin       Date:  2000-11       Impact factor: 3.806

Review 4.  Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Ann Neurol       Date:  2011-10       Impact factor: 10.422

Review 5.  Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease.

Authors:  John H Morrison; Patrick R Hof
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

6.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

7.  Age and Alzheimer's disease gene expression profiles reversed by the glutamate modulator riluzole.

Authors:  A C Pereira; J D Gray; J F Kogan; R L Davidson; T G Rubin; M Okamoto; J H Morrison; B S McEwen
Journal:  Mol Psychiatry       Date:  2016-03-29       Impact factor: 15.992

8.  2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis Clement; Antonio Coca; Giovanni De Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland Schmieder; Evgeny Shlyakhto; Konstantinos Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  J Hypertens       Date:  2018-12       Impact factor: 4.844

Review 9.  Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.

Authors:  Dagmar E Ehrnhoefer; Bibiana K Y Wong; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2011-10-21       Impact factor: 84.694

Review 10.  Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma.

Authors:  Alexandre Vallée; Yves Lecarpentier
Journal:  Front Neurosci       Date:  2016-10-19       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.